He noted that other assays studied in pancreatic cancer have only examined a handful of samples. "When they publish a second ...

Hepatocellular carcinoma (HCC) generally develops as a ... The identifiable population at risk makes screening a realistic possibility, and liver imaging is recommended every 6 months for patients ...

This document, on the diagnosis and treatment of patients with hepatocellular carcinoma (HCC), was commissioned by the ... Because of the lack of screening programmes and the fact that a significant ...

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

On 12 Feb 2025, Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an ...

a Class A: 5–6 points, Class B: 7–9 points, Class C: 10–15 points. Abbreviations: PT; prothrombin time; INR, International Normalized Ratio. When localized HCC is discovered in patients with ...

HealthDay News — A blood-based test (Freenome) may provide a new option for colorectal cancer (CRC) screening in the average-risk U.S. population, according to a study presented at the American ...

CLINICAL complete response (cCR) is a strong predictor of prognosis in patients with unresectable hepatocellular carcinoma ...

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Non-communicable diseases rank among the most serious global health challenges of the 21st century due to their high prevalence and substantial socioeconomic and health-care impact. According to WHO, ...